TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38853958

Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy (MBLT); n=80; 60-min duration; daily over 28-day duration.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham: deactivated negative ion generator; n=40; 60-min duration; daily over 28-day duration.
Number of subjects: 120
Study: 38854081

Group type: EXPERIMENTAL
Intervention: LAFIYA intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 240
Study: 38854091

Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg every 12h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg every 12h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 38854392

Group type: EXPERIMENTAL
Intervention: Ensovibep (75, 225, or 600 mg)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 38854417

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (BID)
Number of subjects: 4967
Study: 38854418

Group type: EXPERIMENTAL
Intervention: Walking exercise (30 minutes, five times per week for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study: 38854653

Group type: EXPERIMENTAL
Intervention: Intervention (high-risk strategy for prevention of cardiovascular diseases)
Number of subjects: 5654

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 5654
Study: 38854740

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 52 weeks
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 52 weeks
Number of subjects: 303
Study: 38854853

Group type: EXPERIMENTAL
Intervention: PRISM 2.0 software
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard Tablet (Control)
Number of subjects: 245
Study: 38854963

Group type: EXPERIMENTAL
Intervention: Submaximal balloon angioplasty (SBA) combined with standard medical therapy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 416
Study: 38855456

Group type: EXPERIMENTAL
Intervention: SAFPAS mobile application
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 20
Study: 38855639

Group type: EXPERIMENTAL
Intervention: IFIP intervention including implementation interventions and clinical interventions (BFIS and FPE)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: IFIP intervention
Number of subjects: 231
Study: 38855751

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Atorvastatin (80 mg) once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoxetine + Placebo once daily
Number of subjects: 60
Study: 38856026

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg and 300 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Bupropion arms
Number of subjects: 230
Study: 38856101

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) and rituximab (RTX) maintenance (R2) after bendamustine and rituximab induction (BR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) and rituximab (RTX) maintenance (R2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bendamustine and rituximab induction (BR)
Number of subjects: 36
Study: 38856176

Group type: EXPERIMENTAL
Intervention: Ixazomib plus daratumumab and dexamethasone (IDd)
Number of subjects: 61
Study: 38856224

Group type: EXPERIMENTAL
Intervention: 5 mg tirzepatide
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 10 mg tirzepatide
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 15 mg tirzepatide
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 38856631

Group type: COMPARATOR
Intervention: ECMO duration of 0-3 days
Number of subjects: 2021

Group type: COMPARATOR
Intervention: ECMO duration of 4-7 days
Number of subjects: 2021

Group type: COMPARATOR
Intervention: ECMO duration of 8-10 days
Number of subjects: 2021

Group type: COMPARATOR
Intervention: ECMO duration of greater than 10 days
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: ECMO duration greater than 7 days
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Post-discharge survival
Number of subjects: 2021
Study: 38856678

Group type: EXPERIMENTAL
Intervention: Evinacumab 15 mg/kg every 4 weeks with stable lipid-lowering therapy
Number of subjects: 116
Study: 38856863

Group type: EXPERIMENTAL
Intervention: BAY 3375968 (anti-human CCR8 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 3375968 (anti-human CCR8 antibody) in combination with immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study: 38856885

Group type: EXPERIMENTAL
Intervention: Novel treatment planning process focused on shared decision-making (SDM)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard-of-care treatment planning process
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Oncologist engagement with patient-reported data
Number of subjects: 109
Study: 38856950

Group type: EXPERIMENTAL
Intervention: High muscular fitness (HMF)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High isometric strength (HIS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High countermovement jump (HCMJ)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low isometric and low dynamic force values (LMF)
Number of subjects: 59
Study: 38856994

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 260
Study: 38857015

Group type: EXPERIMENTAL
Intervention: Aggressive antipyretic therapy (acetaminophen 30 mg/kg load, then 15 mg/kg plus ibuprofen 10 mg/kg every 6 hours for 72 hours)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Aggressive antipyretic therapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (15 mg/kg of acetaminophen as needed every 6 hours for temperature of 38.5 °C or higher)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study: 38857019

Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1140
Study: 38857209

Group type: EXPERIMENTAL
Intervention: Nutrient warning
Number of subjects: 8004

Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 8004

Group type: COMPARATOR
Intervention: No label
Number of subjects: 8004

Group type: COMPARATOR
Intervention: GDA label
Number of subjects: 8004
Study: 38857379

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38857463

Group type: EXPERIMENTAL
Intervention: Subcutaneous amivantamab-lazertinib
Number of subjects: 418

Group type: COMPARATOR
Intervention: Intravenous amivantamab-lazertinib
Number of subjects: 418
Study: 38857500

Group type: EXPERIMENTAL
Intervention: Heat exposure (core temperature increase of 1.5 °C)
Number of subjects: 61
Study: 38857509

Group type: EXPERIMENTAL
Intervention: Individualized opioid-prescription protocol (IOPP) with shared decision making
Number of subjects: 5521

Group type: COMPARATOR
Intervention: Fixed quantity (20 tablets of 5 mg oxycodone)
Number of subjects: 5521
Study: 38857611

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg orally per day) plus usual care
Number of subjects: 3144

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg orally per day)
Number of subjects: 3144
Study: 38857688

Group type: EXPERIMENTAL
Intervention: Stepwise escalating energy algorithm (RaA, 150 J, 360 J, and 360 J)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Maximum fixed energy algorithm (MfA, 3 x 360 J)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Stepwise escalating energy algorithm (RaA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Maximum fixed energy algorithm (MfA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 300
Study: 38857788

Group type: EXPERIMENTAL
Intervention: Survodutide 0.3 mg (single subcutaneous dose)
Number of subjects: 41
Study: 38857811

Group type: EXPERIMENTAL
Intervention: Virtual reality + Pulmonary rehabilitation (VR + PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional Pulmonary rehabilitation (PR)
Number of subjects: 50
Study: 38857913

Group type: EXPERIMENTAL
Intervention: Single-cell RNA analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunofluorescence experiments
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Publicly available transcriptomics data sets
Number of subjects: 30
Study: 38857986

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: T-MACS model
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: CTCA
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: T-MACS estimate <0.05
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: HEART score <4
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: GRACE score <109
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Combination of T-MACS estimates and CTCA findings
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: T-MACS estimate <0.05 and normal coronary arteries
Number of subjects: 699
Study: 38858103

Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine-gynx 6 mg/kg IV every 3 weeks until progression or unacceptable toxicity
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine-gynx
Number of subjects: 105
Study: 38858106

Group type: EXPERIMENTAL
Intervention: Tiragolumab plus atezolizumab (tiragolumab 600 mg + atezolizumab 1200 mg every 3 weeks)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Atezolizumab alone (1200 mg every 3 weeks)
Number of subjects: 171
Study: 38858139

Group type: EXPERIMENTAL
Intervention: 22-month household-based counselling intervention
Number of subjects: 16301
Study: 38858145

Group type: EXPERIMENTAL
Intervention: SABA prescriptions (≥3 SABA canisters/year)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: SABA in addition to maintenance therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: SABA canisters (≥3 vs 0-2 canisters)
Number of subjects: 205
Study: 38858147

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control (standard antiplatelet therapy)
Number of subjects: 516
Study: 38858151

Group type: EXPERIMENTAL
Intervention: Donor FMT (from two different donors)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Autologous FMT (placebo)
Number of subjects: 80
Study: 38858157

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 38858161

Group type: EXPERIMENTAL
Intervention: Venoarterial ECMO treatment
Number of subjects: 64
Study: 38858375

Group type: EXPERIMENTAL
Intervention: Mobile game therapy intervention for ADHD, 4-week home-based game intervention.
Number of subjects: 110
Study: 38858465

Group type: EXPERIMENTAL
Intervention: Maternal exercise (moderate-intensity) during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 0
Study: 38858523

Group type: EXPERIMENTAL
Intervention: Retatrutide 1 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 38858569

Group type: EXPERIMENTAL
Intervention: RNA delivery
Number of subjects: 0
Study: 38858629

Group type: EXPERIMENTAL
Intervention: Treatment as Usual + Mindfulness (TaU + MIND)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 177
Study: 38858721

Group type: EXPERIMENTAL
Intervention: Pre-treatment peripheral blood myeloid cells in TNBC
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pre-treatment CD8+ naive T cells and CD4+ effector memory cells re-expressing CD45RA in hormone receptor-positive breast cancer
Number of subjects: 126
Study: 38858743

Group type: EXPERIMENTAL
Intervention: Experimental psychoeducational intervention targeting insomnia (B2)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Digital psychological control intervention (B1)
Number of subjects: 114
Study: 38858795

Group type: EXPERIMENTAL
Intervention: Neural Pressure Support (NPS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Pressure Support Ventilation (PSV)
Number of subjects: 24
Study: 38858818

Group type: EXPERIMENTAL
Intervention: Finerenone 10 or 20 mg depending on eGFR above or below 60 mL/min/1.73 m2
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 1584
Study: 38859627

Group type: EXPERIMENTAL
Intervention: Flapless procedure with enamel matrix derivatives (EMD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Flapless procedure alone
Number of subjects: 46
Study: 38859640

Group type: EXPERIMENTAL
Intervention: Exercise intervention targeting hip strengthening (NEMEX-STR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard community-based rehabilitation (Usual care)
Number of subjects: 84
Study: 38859644

Group type: EXPERIMENTAL
Intervention: Reduced-dose edoxaban (30 mg)
Number of subjects: 586
Study: 38859744

Group type: EXPERIMENTAL
Intervention: Erenumab treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: No CGRP-induced migraine (Control)
Number of subjects: 139
Study: 38859822

Group type: EXPERIMENTAL
Intervention: Clustering methodology applied to caregiver experience profiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support interventions tailored to caregiver experience profiles
Number of subjects: 0
Study: 38859883

Group type: EXPERIMENTAL
Intervention: Intravenous odatroltide (0.025 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 38860025

Group type: EXPERIMENTAL
Intervention: TDF/FTC PrEP (two, four, or seven doses per week for 8 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TDF/FTC PrEP (seven doses per week for 8 weeks)
Number of subjects: 45
Study: 38860054

Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index, PSQI)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Low EQ-5D score
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Greater Cognitive Reserve Questionnaire (CRC) score
Number of subjects: 499
Study: 38860057

Group type: EXPERIMENTAL
Intervention: Bluetooth noise-canceling headphones
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (smartphone at normal speech volume 60 decibels)
Number of subjects: 29
Study: 38860154

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 88

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study: 38860389

Group type: EXPERIMENTAL
Intervention: AIH+HIT
Number of subjects: 35

Group type: COMPARATOR
Intervention: normoxia+HIT
Number of subjects: 35
Study: 38860394

Group type: EXPERIMENTAL
Intervention: Higher lipoprotein(a) ≥150 nmol/L
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Higher oxidized phospholipid concentrations
Number of subjects: 714

Group type: COMPARATOR
Intervention: Stage A/B HF
Number of subjects: 714
Study: 38860396

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 5796

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 5796
Study: 38860554

Group type: EXPERIMENTAL
Intervention: Meal habit recommendations (breakfast and late-evening snack habits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 38860591

Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 dose 4 in 6-month- to <5-year-olds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 in 5- to <12-year-olds
Number of subjects: 0

Group type: COMPARATOR
Intervention: original BNT162b2 dose 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 dose 4
Number of subjects: 0
Study: 38860727

Group type: EXPERIMENTAL
Intervention: Progressive exercise therapy (PR)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 79
Study: 38860901

Group type: EXPERIMENTAL
Intervention: Vortioxetine (detailed dosage and duration not specified)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 142
Study: 38860935

Group type: EXPERIMENTAL
Intervention: Intravaginal Er:YAG laser (nonablative, Smooth mode, 2,940 nm)
Number of subjects: 20
Study: 38860996

Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 646
Study: 38861137

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 187
Study: 38861192

Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6
Number of subjects: 89

Group type: COMPARATOR
Intervention: placebo-mFOLFOX6
Number of subjects: 89
Study: 38861286

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regorafenib (lower starting doses)
Number of subjects: 0
Study: 38861294

Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38861293

Group type: EXPERIMENTAL
Intervention: CTX-009 with paclitaxel
Number of subjects: 0
Study: 38861301

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus tiragolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab plus bevacizumab
Number of subjects: 0
Study: 38861324

Group type: EXPERIMENTAL
Intervention: Individualized anemia therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38861361

Group type: EXPERIMENTAL
Intervention: Resin 90 Y radioembolization
Number of subjects: 30
Study: 38861398

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Reprogramming to the secondary vector
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: System removal and subsequent S-ICD reimplantation
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: S-ICD system exchange
Number of subjects: 1158
Study: 38861659

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavior therapy (bCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 0
Study: 38861666

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib plus venetoclax (PV)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib plus venetoclax and rituximab (PVR)
Number of subjects: 25
Study: 38861681

Group type: EXPERIMENTAL
Intervention: Hearing aids (HA) fitted for 1 year
Number of subjects: 86
Study: 38861707

Group type: EXPERIMENTAL
Intervention: POSSIBLE intervention using the PrEPme app and peer change agent (PCA)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: POSSIBLE intervention
Number of subjects: 69
Study: 38861793

Group type: EXPERIMENTAL
Intervention: High calcium (shake containing 700 mg Ca/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low calcium (shake with 6.4 mg Ca/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups on energy-restricted diets (-500 kcal/d, 800 mg of dietary Ca/d)
Number of subjects: 14
Study: 38861871

Group type: EXPERIMENTAL
Intervention: palbociclib plus letrozole
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 1186

Group type: COMPARATOR
Intervention: placebo plus letrozole
Number of subjects: 1186

Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 1186
Study: 38861890

Group type: EXPERIMENTAL
Intervention: American Heart Association (AHA diet)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mediterranean pattern diet (FLiO diet)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Baseline chemerin, leptin, LECT2, and M65
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Inflammatory markers (leptin, adiponectin, M30, LECT2)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (forty-five subjects)
Number of subjects: 98
Study: 38861967

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38862073

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mononuclear cells
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 110
Study: 38862134

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 647

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 647
Study: 38862179

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Ticagrelor monotherapy (90 mg twice daily)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Aspirin monotherapy (100 mg once daily)
Number of subjects: 500
Study: 38862183

Group type: EXPERIMENTAL
Intervention: NIS burden of ≥3
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Improved NIS burden
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: NIS management
Number of subjects: 111
Study: 38862220

Group type: EXPERIMENTAL
Intervention: Nucleic acid amplification test (NAAT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard of care (syndromic management)
Number of subjects: 220
Study: 38862228

Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: WHO Disability Assessment Schedule (WHODAS) 2.0
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Mortality follow-up
Number of subjects: 1750
Study: 38862251

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab 240 mg every 3 weeks (three cycles) combined with axitinib 5 mg twice daily for up to 12 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab combined with axitinib.
Number of subjects: 20
Study: 38862308

Group type: EXPERIMENTAL
Intervention: Routine care plus peer-led vaccine counseling
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 144